RT Journal Article
SR Electronic
T1 Gallium-68-Pentixafor PET/CT demonstrating in vivo CXCR4 receptors’ overexpression in rare lung malignancies: Correlation with the histological and histochemical findings
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP jnmt.122.264141
DO 10.2967/jnmt.122.264141
A1 Watts, Ankit
A1 Singh, Baljinder
A1 Singh, Harmandeep
A1 Kaur, Harneet
A1 Bal, Amanjit
A1 Vohra, Mehak
A1 Arora, Sunil K
A1 Behera, Digambar
YR 2022
UL http://tech.snmjournals.org/content/early/2022/05/24/jnmt.122.264141.abstract
AB Objectives: Gallium-68 [68Ga] Pentixafor PET/CT imaging allows non-invasive assessment of CXCR4 expression in various malignancies, but its use in rare lung cancer variants is not reported. Methods: [68Ga] Pentixafor PET/CT imaging was performed in 6 patients (3M:3F; mean age=57.0±16.80 years) with suspected lung masses. Whole-body PET/CT images were acquired at 1-h after the i.v. injection of 148.0-185.0 MBq of the tracer. PET/CT images were reconstructed and analysed. The image findings were correlated with histopathological and quantitative (CXCR4-receptors) FACS analysis. Results: Histopathological diagnosis of haemangioendothelioma, sarcomatoid carcinoma and hemangiopericytoma was confirmed in 1-patient each. Lung metastasis was diagnosed in the remaining 3/6 patients with primary sarcoma (n = 1), RCC (n = 1) and unknown primary (n = 1). Increased tracer uptake in the primary lung mass with SUVmax values of 3.0, 6.3 and 13.0 were noted in hemangiopericytoma, sarcomatoid carcinoma and haemangioendothelioma cases respectively. The mean values of SUVmax, MFI and % stained cells were highest in haemangioendothelioma. Among 3 patients with lung metastases, the highest SUVmax value of 9.5 was observed in primary sarcoma patient. Conclusion: [68Ga] Pentixafor selectively targets the in vivo whole-body disease burden of CXCR4 receptors. This approach thus holds good promise for developing suitable radio-theranostics in lung cancers expressing these targets.